Final answer:
Caution or avoidance of rivaroxaban is advised for those above 35 who smoke, have a history of blood clots, or have certain types of cancer. Pharmacogenomics can assist warfarin treatments by personalizing dosages to reduce overdose risk. Warfarin dosage adjustment is based on individual genetic makeup influencing liver function and drug metabolism.
Step-by-step explanation:
Individuals should exercise caution or avoid the use of rivaroxaban (Xarelto), a blood thinner, under certain conditions. This includes individuals who are older than 35 and smoke, have a history of blood clots, or have a history of breast, liver, or endometrial cancer. Smoking increases the risk of clotting, thus combining it with anticoagulants like rivaroxaban might increase the risk of bleeding. A history of blood clots or cancer can also alter the way the body handles blood thinners, potentially increasing complications.
In regards to pharmacogenomics, this field of study could be particularly useful in assisting patients taking warfarin (Coumadin). Warfarin requires careful dose management to prevent excessive clotting or dangerous bleeding. Through pharmacogenomic testing, physicians can tailor warfarin dosages based on genetic factors that affect liver function and drug metabolism, thus minimizing the risk of overdose and adverse side effects.